Nature Communications (Mar 2023)
Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
- Michal Canetti,
- Noam Barda,
- Mayan Gilboa,
- Victoria Indenbaum,
- Michal Mandelboim,
- Tal Gonen,
- Keren Asraf,
- Yael Weiss-Ottolenghi,
- Sharon Amit,
- Ram Doolman,
- Ella Mendelson,
- Dror Harats,
- Laurence S. Freedman,
- Yitshak Kreiss,
- Yaniv Lustig,
- Gili Regev-Yochay
Affiliations
- Michal Canetti
- The Infection Prevention & Control Unit, Sheba Medical Center, Tel Hashomer
- Noam Barda
- ARC Innovation Center, Sheba Medical Center, Tel Hashomer
- Mayan Gilboa
- The Infection Prevention & Control Unit, Sheba Medical Center, Tel Hashomer
- Victoria Indenbaum
- Sackler School of Medicine, Tel-Aviv University
- Michal Mandelboim
- Sackler School of Medicine, Tel-Aviv University
- Tal Gonen
- The Infection Prevention & Control Unit, Sheba Medical Center, Tel Hashomer
- Keren Asraf
- Sackler School of Medicine, Tel-Aviv University
- Yael Weiss-Ottolenghi
- The Infection Prevention & Control Unit, Sheba Medical Center, Tel Hashomer
- Sharon Amit
- Sackler School of Medicine, Tel-Aviv University
- Ram Doolman
- Sackler School of Medicine, Tel-Aviv University
- Ella Mendelson
- Sackler School of Medicine, Tel-Aviv University
- Dror Harats
- General Management, Sheba Medical Center, Tel Hashomer
- Laurence S. Freedman
- Biostatistics and Biomathematics Unit, Gertner Institute of Epidemiology and Health Policy Research, Sheba Medical Center
- Yitshak Kreiss
- Sackler School of Medicine, Tel-Aviv University
- Yaniv Lustig
- Sackler School of Medicine, Tel-Aviv University
- Gili Regev-Yochay
- The Infection Prevention & Control Unit, Sheba Medical Center, Tel Hashomer
- DOI
- https://doi.org/10.1038/s41467-023-37338-7
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 1
Abstract
No abstracts available.
